The study assessed 20 healthy adult volunteers, administering MRX1 twice daily at levels of 2.5 mg/kg and 7.5 mg/kg. Participants showed no moderate or severe adverse events, and no individuals withdrew from the trial due to complications. Crucially, the data showed no significant shifts in laboratory parameters, including liver function, aligning the drug's performance with established standards for approved CBD therapies.

CEO Melissa Sturgess noted that these results validate the company's clinical and regulatory strategy, particularly its FDA 505(b)(2) development pathway. The findings provide the necessary groundwork for the upcoming ENDOCAN and ACTION trials, which are supported by funding from NHS Scotland and the NIHR EME grant respectively. Researchers also evaluated the impact of food on drug absorption, testing a single 2.5 mg/kg dose after a high-fat meal to ensure consistent therapeutic delivery. Having cleared this safety milestone, Ananda Pharma aims to begin patient dosing for its Phase 2 programs in the second half of 2026.